Orexigen Therapeutics stock price, funding rounds, valuation and financials

Orexigen Therapeutics has raised $76 m in total funding. Orexigen Therapeutics annual revenue was $33.71 m in FY 2016

$18.9 M

Orexigen Therapeutics Revenue Q3, 2017
Orexigen Therapeutics Gross profit (Q3, 2017)14.9 M
Orexigen Therapeutics Gross profit margin (Q3, 2017), %78.6%
Orexigen Therapeutics Net income (Q3, 2017)-20.8 M
Orexigen Therapeutics EBIT (Q3, 2017)-22.8 M
Orexigen Therapeutics Cash, 30-Sept-201745.6 M
Get notified regarding key financial metrics and revenue changes at Orexigen TherapeuticsLearn more
Banner background

Orexigen Therapeutics Funding

Summary Metrics

Founding Date

2002

Orexigen Therapeutics total Funding

$76 m

Orexigen Therapeutics latest funding size

$30 m

Time since last funding

15 years ago

Orexigen Therapeutics investors

Orexigen Therapeutics's latest funding round in November 2006 was reported to be $30 m. In total, Orexigen Therapeutics has raised $76 m

Orexigen Therapeutics Capital Raised

Embed Graph

Orexigen Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

4.4m3.4m3.4m55.5m24.5m33.7m

Revenue growth, %

1520%(56%)38%

Cost of goods sold

8.0m

Gross profit

25.7m

Gross profit Margin, %

76%

R&D expense

12.8m73.7m56.7m57.4m40.8m38.0m

General and administrative expense

19.5m20.0m23.9m28.6m43.8m118.6m

Operating expense total

32.3m93.7m80.6m86.1m84.5m82.7m

Depreciation and amortization

3.3m

EBIT

(27.9m)(90.2m)(77.2m)(30.5m)(60.1m)(57.0m)

EBIT margin, %

(634%)(2632%)(2252%)(55%)(246%)(169%)

Interest expense

221.0k2.0k

Interest income

46.0k147.0k65.0k88.0k227.0k622.0k

Pre tax profit

(67.3m)(24.4m)

Income tax expense

1.4m133.0k

Net Income

(28.1m)(90.1m)(77.7m)(37.5m)(68.7m)(24.5m)

Orexigen Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

101.7m78.3m98.1m104.2m155.4m92.5m

Accounts Receivable

2.6m6.8m1.1m

Prepaid Expenses

1.1m1.5m1.3m1.5m2.3m

Inventories

1.2m10.8m23.2m

Current Assets

148.7m138.9m178.3m211.3m233.9m224.5m

PP&E

439.0k83.0k630.0k857.0k1.3m1.0m

Total Assets

149.7m139.2m180.1m213.0m236.6m304.6m

Accounts Payable

1.5m3.8m4.8m4.2m6.5m15.2m

Current Liabilities

7.7m25.1m22.9m29.7m32.2m65.4m

Long-term debt

80.0m83.9m88.1m

Total Debt

83.9m

Common Stock

61.0k84.0k105.0k123.0k146.0k

Additional Paid-in Capital

446.4m512.2m556.2m574.2m653.7m698.2m

Retained Earnings

(346.7m)(436.8m)(514.5m)(552.0m)(620.7m)(645.2m)

Total Equity

99.7m75.5m41.9m22.3m33.4m57.0m

Financial Leverage

1.5 x1.8 x4.3 x9.5 x7.1 x5.3 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

36.4m33.9m73.4m67.4m56.1m67.1m55.8m48.7m37.6m31.1m68.4m75.1m71.6m154.3m68.0m78.2m74.4m76.7m36.7m45.6m

Accounts Receivable

32.0m4.5m6.8m4.6m2.8m2.9m2.1m6.3m7.6m19.1m

Prepaid Expenses

1.3m897.0k1.3m2.3m1.5m2.0m3.0m1.8m1.3m5.8m1.8m1.3m2.0m2.2m2.6m4.0m6.1m4.9m4.3m6.5m

Inventories

754.0k1.4m4.9m11.1m15.0m11.5m24.0m20.7m15.8m16.1m

Current Assets

71.0m64.7m139.9m128.5m109.8m116.6m99.0m84.6m156.4m139.1m153.2m196.4m189.3m251.8m262.4m282.7m273.2m158.5m114.3m112.3m

PP&E

654.0k546.0k319.0k242.0k166.0k7.0k4.0k120.0k650.0k675.0k718.0k817.0k765.0k931.0k1.4m1.4m1.3m927.0k814.0k702.0k

Total Assets

72.3m65.9m140.7m128.9m110.1m116.7m99.2m85.7m158.1m140.9m154.5m198.0m191.2m254.3m375.0m345.4m355.8m236.4m190.0m183.7m

Accounts Payable

5.6m3.5m5.0m3.0m4.6m4.8m5.0m5.0m5.4m8.1m4.7m2.5m6.6m3.9m4.6m4.1m12.0m15.6m8.3m10.9m

Short-term debt

205.0k

Current Liabilities

9.2m7.0m8.4m11.8m21.2m20.4m18.6m20.9m21.7m24.6m21.7m25.9m36.6m35.4m30.4m34.8m65.5m49.5m41.8m56.2m

Long-term debt

81.0m81.9m82.9m84.9m86.0m87.0m209.0m206.4m200.9m177.2m171.5m171.6m

Total Debt

205.0k81.0m81.9m82.9m84.9m86.0m87.0m209.0m206.4m200.9m177.2m171.5m171.6m

Common Stock

48.0k48.0k68.0k68.0k71.0k93.0k98.0k99.0k112.0k123.0k123.0k125.0k125.0k145.0k146.0k15.0k15.0k15.0k15.0k16.0k

Additional Paid-in Capital

356.7m358.1m448.0m450.4m453.6m514.7m518.0m521.6m560.1m564.3m569.4m581.3m587.4m650.6m656.5m659.1m695.8m703.9m706.8m710.6m

Retained Earnings

(337.8m)(342.4m)(357.1m)(373.8m)(404.3m)(456.2m)(474.4m)(493.0m)(539.4m)(563.9m)(552.6m)(569.2m)(591.7m)(602.9m)(643.0m)(668.3m)(620.6m)(714.3m)(744.8m)(765.6m)

Total Equity

19.0m15.8m90.9m76.6m49.4m58.6m43.7m28.7m20.9m547.0k16.9m12.3m(4.2m)46.2m10.9m(10.0m)73.4m(7.9m)(42.0m)(62.4m)

Financial Leverage

3.8 x4.2 x1.5 x1.7 x2.2 x2 x2.3 x3 x7.6 x257.5 x9.1 x16.2 x-45.2 x5.5 x34.5 x-34.5 x4.8 x-30.1 x-4.5 x-2.9 x

Orexigen Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.1m)(90.1m)(77.7m)(37.5m)(68.7m)(24.5m)

Depreciation and Amortization

443.0k313.0k94.0k139.0k223.0k3.7m

Accounts Receivable

(2.5m)(4.3m)5.7m

Inventories

(1.2m)(9.6m)1.5m

Accounts Payable

(6.1m)17.3m(2.3m)2.1m1.0m11.8m

Cash From Operating Activities

(29.2m)(68.3m)(70.8m)26.8m(54.5m)(109.7m)

Purchases of PP&E

(640.0k)(246.0k)(538.0k)(330.0k)

Cash From Investing Activities

21.1m(13.3m)(21.3m)(23.4m)41.4m(107.1m)

Long-term Borrowings

(2.4m)

Cash From Financing Activities

85.0m58.3m111.9m2.7m64.3m154.6m

Net Change in Cash

76.8m(23.4m)19.8m6.1m51.2m(62.9m)

Interest Paid

29.0k3.1m3.2m3.2m

Income Taxes Paid

28.0k1.3m

Quarterly

Orexigen Therapeutics Ratios

USDQ2, 2011

Financial Leverage

3.8 x

Orexigen Therapeutics Employee Rating

3.513 votes
Culture & Values
3.5
Work/Life Balance
3.4
Senior Management
3.7
Salary & Benefits
3.9
Career Opportunities
2.9
Source